Catalog No.
Product Name
Application
Product Information
Citations
-
EGFR Inhibitor
Tyrphostin AG213 is a selective inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.85 μM, targeting its protein tyrosine kinase activity. In addition to its primary function, Tyrphostin AG213 also inhibits tyrosine kinase activity with an IC50 of 2.4 μM and topoisomerase II, exhibiting an IC100 of 50 μM. This compound has been shown to induce non-apoptotic programmed cell death in tumor cells, making it a valuable tool for cancer research and potential therapeutic applications. -
EGFR Inhibitor
EGFR-IN-67 is a potent inhibitor of the epidermal growth factor receptor (EGFR), exhibiting an IC50 value of 0.34 μM. This compound demonstrates significant anticancer activity, making it a valuable tool for research in cancer biology and targeted therapeutic strategies against EGFR-overexpressing tumors. Researchers can utilize EGFR-IN-67 to investigate the role of EGFR signaling in various cancer types and explore potential treatment modalities. -
EGFR Inhibitor
EG31 is a potent inhibitor of the epidermal growth factor receptor (EGFR), exhibiting strong antiproliferative effects on triple-negative breast cancer (TNBC) cells, with GI50 values of 498.90 nM for MDA-MB-231 and 740.73 nM for Hs578T cell lines. It effectively induces apoptosis by disrupting the EGFR signaling pathway. Additionally, EG31 retains its efficacy against 5-fluorouracil (5-FU)-resistant TNBC cells, demonstrating a GI50 of 519.5 nM. This compound is valuable for researching mechanisms of resistance in TNBC. -
EGFR Inhibitor
EGFR-IN-201 is a potent inhibitor of the epidermal growth factor receptor (EGFR), exhibiting an IC50 of 0.091 μM against wild-type EGFR. It demonstrates activity against mutant EGFR variants, with IC50 values of 0.147 μM for EGFRT790M, 0.221 μM for EGFRL858R, and 0.703 μM for EGFRC797S. Inhibition of downstream signaling pathways is evidenced by its IC50 values of 0.225 μg/mL for AKT1 and 0.705 μg/mL for ERK1. EGFR-IN-201 has been shown to induce G0/G1 cell cycle arrest, apoptosis, and low-level necrosis in cancer cells, making it a valuable tool for research in various cancer types, including colon cancer. -
EGFR L858R/T790 Inhibitor
EGFR T790M/L858R-IN-7 is a potent inhibitor of the EGFR L858R and T790M mutations, demonstrating a remarkable 93% inhibition rate at a concentration of 0.05 μM. This novel pyrimidine compound operates by selectively targeting the kinase domain of the epidermal growth factor receptor (EGFR), effectively suppressing its phosphorylation activity. It is a valuable tool for research applications focused on understanding resistance mechanisms in non-small cell lung cancer (NSCLC) and developing targeted therapies. -
EGFR Inhibitor
AZ5385 is an EGFR-tyrosine kinase inhibitor that effectively modulates signaling pathways involved in cell proliferation and survival. This compound also demonstrates antiviral activity, specifically against HRV-2, with an EC50 value of 0.35 µM, targeting the late stages of the viral life cycle. AZ5385 is applicable in research focusing on cancer therapeutics and virology studies. -
EGFR Tyrosine Kinase Inhibitor
BPIQ-I is a potent ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It exhibits significant anti-proliferative activity in various cancer cell lines by interfering with downstream signaling pathways essential for tumor growth and survival. This compound is primarily utilized in cancer research to elucidate the role of EGFR in oncogenic processes and to explore therapeutic strategies targeting EGFR-mediated signaling. -
EGFR Inhibitor
EGFR-IN-101 is a selective inhibitor of the epidermal growth factor receptor (EGFR). This compound demonstrates potent inhibitory activity with IC50 values of 33.26 nM against the EGFRL858R/T790M/C797S mutation and 106.4 nM in Ba/F3-EGFRL858R/T790M/C797S cells. EGFR-IN-101 is valuable for research applications focused on non-small cell lung cancer (NSCLC) and provides a framework for investigating resistance mechanisms and therapeutic strategies targeting EGFR mutations. -
EGFR Inhibitor
NSC114126 is a highly effective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. This compound demonstrates significant antiproliferative activity, making it a valuable tool for cancer research. Its potency and oral bioavailability facilitate the study of EGFR-related pathways in various cancer mechanisms. -
EGFR Inhibitor
EGFR-IN-180 is a potent inhibitor of the epidermal growth factor receptor (EGFR), specifically targeting both wild-type and the drug-resistant L858R/T790M/C797S mutation, with IC50 values of 80.96 nM and 16.43 nM, respectively. This compound serves as an important tool for investigating therapeutic options in non-small cell lung cancer (NSCLC) research, enabling studies on resistance mechanisms and potential combination therapies. Its specific action on EGFR pathways makes it a valuable reagent in cancer biology and pharmacological development. -
EGFR Inhibitor
EGFR-IN-64 is a selective inhibitor of the epidermal growth factor receptor (EGFR), demonstrating significant potency with an IC50 value of 0.33 μM. This compound has been identified for its potential anticancer activity, making it a valuable tool for research focused on EGFR-related signaling pathways and therapeutic strategies in oncology. Researchers may utilize EGFR-IN-64 to explore the mechanisms of tumor growth and resistance in EGFR-driven cancers. -
EGFR Inhibitor
EGFR-IN-54 is a potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating an IC50 of 1.623 µM. This compound exhibits significant cytotoxic activity against various cancer cell lines, making it a valuable tool for cancer research. Its inhibitory effects on EGFR can be utilized in studies aimed at understanding cancer proliferation and developing targeted therapies. -
EGFR Inhibitor
EGFR-IN-147 is a potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating an inhibition rate of 14% at a concentration of 1 μM. This compound plays a critical role in cancer research, providing a valuable tool for investigating EGFR-related signaling pathways and therapeutic interventions in various malignancies. Its specificity towards EGFR can aid in studies aimed at understanding tumor growth and resistance mechanisms. -
EGFR Inhibitor
Tesevatinib tosylate is a potent inhibitor of the epidermal growth factor receptor (EGFR), capable of penetrating the blood-brain barrier. This compound exhibits significant cytotoxic effects, demonstrating IC50 values of 11 nM and 102 nM against GBM12 and GBM6 cell lines, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50 = 16.1 nM), VEGFR2 (IC50 = 1.5 nM), and Src (IC50 = 10.3 nM), making it a valuable tool for studying tumor proliferation and antitumor activity in various cancer research applications. -
EGFR/HER2 Inhibitor
EGFR/HER2/TS-IN-2 is a potent inhibitor targeting the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and thymidylate synthase (TS), demonstrating IC50 values of 0.173, 0.125, and 1.12 µM, respectively. This compound exhibits significant cytotoxic activity against MDA-MB-231 breast cancer cell lines, with an IC50 of 1.69 µM. It is a valuable tool for research focused on cancer therapy and the study of tumor biology related to EGFR and HER2 signaling pathways. -
EGFR Inhibitor
EGFR-IN-177 is a highly selective inhibitor of the epidermal growth factor receptor (EGFR), exhibiting IC50 values of 0.32 nM against the EGFR L858R mutation and 0.67 nM against EGFR D746-750, among others. This compound effectively inhibits lung cancer cell proliferation and the phosphorylation of EGFR, demonstrating significant potential for therapeutic applications in non-small cell lung cancer research. EGFR-IN-177 is a valuable tool for exploring mechanisms of resistance and sensitivity in targeted cancer therapies. -
EGFR Inhibitor
EGFR-IN-126 is a potent inhibitor targeting the EGFRL858R/T790M/C797S mutations, exhibiting an IC50 value of 0.005 μM. This compound demonstrates significant antitumor activity in both in vivo and in vitro models, making it a valuable tool for cancer research and therapeutic development focusing on EGFR-related malignancies. -
EGFR/HER2 Inhibitor
EGFR/HER2-IN-4 is an irreversible dual inhibitor targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It exhibits potent inhibition of EGFR with an IC50 of 0.6 nM and effectively inhibits kinase activity associated with L858R and T790M mutations. Demonstrating significant antitumor efficacy in vivo, EGFR/HER2-IN-4 is a valuable reagent for research on lung cancer and related therapeutic strategies. -
EGFR Inhibitor
EGFR-IN-203 is a selective inhibitor of the EGFR kinase domain, specifically targeting the mutant forms EGFRT790M, C797S, and V948R. It exhibits a stable binding affinity to the allosteric pocket of EGFR in its inactive conformation. This compound is valuable for research applications focused on cancer, particularly non-small cell lung cancer, providing insights into EGFR-related pathways and potential therapeutic strategies. -
EGFR T790M/L858R Inhibitor
EGFR T790M/L858R-IN-5 is a selective inhibitor targeting the EGFR T790M and L858R mutations. It demonstrates a high inhibition percentage of 92.9% at a concentration of 0.05 μM, making it a valuable tool for research into targeted cancer therapies. This compound is primarily utilized in studies aimed at understanding resistance mechanisms in non-small cell lung cancer and the development of effective treatment strategies. -
EGFR Inhibitor
EGFR-IN-42 is a potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating single-digit nanomolar activity. This compound forms a covalent linkage between tamoxifen or endoxifen and the EGFR inhibitor gefitinib, allowing it to retain both estrogen receptor antagonist and EGFR inhibitory properties. EGFR-IN-42 shows enhanced anti-cancer activity, making it a valuable tool for research into dual-target therapeutic strategies in cancer treatment. -
EGFR Radiotracer
ODS-2004436 is a small molecule radiotracer that targets the epidermal growth factor receptor (EGFR) for use in positron emission tomography (PET) imaging. This compound exhibits significantly higher uptake in xenograft models of lung cancer harboring EGFR mutations compared to wild-type models, enabling effective differentiation of mutation status. ODS-2004436 is valuable for identifying EGFR-positive tumors and predicting therapeutic responses, particularly in non-small cell lung cancer (NSCLC) research applications. -
EGFR Inhibitor
EGFR-IN-68 is a selective inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.33 μM. This compound demonstrates significant anticancer activity, making it valuable for research on tumor proliferation and metastasis. It is particularly useful in studies examining EGFR signaling pathways and developing targeted therapeutic strategies in cancer biology. -
EGFR Inhibitor
Dacomitinib metabolite M1/2 is a potent inhibitor of epidermal growth factor receptor (EGFR), effective against both wild-type EGFR and the T790M mutation. This compound shows significant activity against acquired resistance mechanisms in EGFR-mutant non-small-cell lung cancer (NSCLC), making it an important tool for researchers studying cancer treatment and resistance pathways. Its role in targeting resistant NSCLC underscores its relevance in the development of therapeutic strategies. -
EGFR Inhibitor
EGFR-IN-55 is a selective inhibitor of the Epidermal Growth Factor Receptor (EGFR), exhibiting potent activities with IC50 values of 70 nM for wild-type EGFR and 3.9 nM for the EGFRL858R/T790M mutant. This compound effectively induces cell cycle arrest in the G0/G1 phase in NCI-H1975 cells, demonstrating significant anticancer activity. EGFR-IN-55 is a valuable tool for research in cancer biology, particularly in studies targeting EGFR-related pathways. -
EGFR Inhibitor
Tyrphostin 25 is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, demonstrating an IC50 of 3 µM in A431 cells. Additionally, this compound acts as an agonist for GPR35, exhibiting an EC50 of 5.3 µM. Tyrphostin 25 is utilized in research applications focused on cancer biology and signal transduction pathways, making it a valuable tool for understanding EGFR-related mechanisms and GPR35 function. -
EGFR Inhibitor
RG-14467 is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, exerting its action by inhibiting enzymatic activity. It exhibits inhibition kinetics comparable to Lavendustin-A, with a dissociation constant of 3.4 μM for the rapidly formed initial complex and an overall dissociation constant estimated at 30 nM or less. RG-14467 functions as a partially competitive inhibitor of ATP, making it a valuable tool for research applications focused on EGFR-related signaling pathways and cancer therapeutics. -
EGFR/HER2 Inhibitor
EGFR/HER2-IN-3 is a potent dual inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It exhibits significant biological activity in inhibiting cell proliferation and tumor growth associated with EGFR and HER2 overexpression. This compound is particularly useful in cancer research, facilitating studies on therapeutic interventions for tumors driven by these pathways. -
EGFR Inhibitor
EGFR-IN-39 is a potent inhibitor of the epidermal growth factor receptor (EGFR), a pivotal target in the regulation of cell proliferation. This acrylamide derivative exhibits significant anti-tumor activity with minimal associated toxicity, making it a valuable candidate for cancer research, particularly concerning non-small cell lung cancer (NSCLC). Given its ability to address conditions linked to EGFR overexpression and mutations, EGFR-IN-39 holds promise for advancing the understanding and treatment of EGFR-driven malignancies. -
EGFR Inhibitor
EGFR-IN-29 is a highly potent inhibitor of the epidermal growth factor receptor (EGFR). This compound demonstrates significant biological activity in blocking EGFR signaling pathways, which are critical in various tumorigenic processes. EGFR-IN-29 is useful in research applications focused on cancer biology and therapeutic resistance, providing insights into targeted therapy for EGFR-driven malignancies. -
EGFR Inhibitor
EGFR-IN-114 is a selective non-covalent inhibitor targeting mutant forms of the epidermal growth factor receptor (EGFR). Demonstrating potent inhibitory activity, it is primarily utilized in research focused on non-small cell lung cancer (NSCLC). This compound provides a valuable tool for studying EGFR signaling pathways and developing targeted therapies in oncological research. -
EGFR Inhibitor
EGFR-IN-133 is a potent inhibitor of the epidermal growth factor receptor (EGFR), effectively targeting various mutations including wildtype, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM, respectively. This compound demonstrates favorable pharmacokinetic properties and exhibits high oral bioavailability, making it a useful tool in molecular biology and cancer research for studying EGFR signaling pathways and developing targeted therapies for EGFR-mutant cancers. -
EGFR Inhibitor
EGFR-IN-37 is a selective inhibitor of epidermal growth factor receptor (EGFR), designed to target and disrupt its activity. This compound exhibits significant anti-tumor effects while minimizing toxic side effects, making it suitable for therapeutic research. Given the role of EGFR overexpression and mutations in driving uncontrolled cell proliferation, particularly in non-small cell lung cancer (NSCLC), EGFR-IN-37 presents a valuable tool for investigating EGFR-related malignancies. Its applications extend to the study of disease mechanisms and potential treatment strategies for conditions associated with EGFR mutations. -
EGFR Inhibitor
EGFR-IN-200 is a selective inhibitor of the epidermal growth factor receptor (EGFR), with IC50 values of 0.03 μM for EGFR, 3.1 μM for TNF-α, and 1.6 μM for the IL-6/GP130 complex. By binding to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, it induces G2/M cell cycle arrest, apoptosis, and demonstrates potent antiproliferative activity. With high gastrointestinal absorption and low blood-brain barrier permeability, EGFR-IN-200 is valuable for investigating mechanisms in lung cancer and breast adenocarcinoma research. -
EGFR Inhibitor
EGFR-IN-110 is a covalent inhibitor of the epidermal growth factor receptor (EGFR), exhibiting pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR-expressing cells. This compound demonstrates robust inhibitory activity against EGFR, coupled with favorable selectivity for kinases. It serves as a valuable tool in research focused on targeting EGFR-related pathways and exploring therapeutic interventions in EGFR-driven cancers. -
EGFR Inhibitor
EGFR-IN-157 is a potent inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 18.81 nM. This compound is primarily utilized in research focused on non-small cell lung cancer (NSCLC), enabling investigations into EGFR-mediated signaling pathways and therapeutic strategies. Its efficacy in inhibiting EGFR activity makes it a valuable tool for studying the molecular mechanisms underlying NSCLC and developing targeted cancer therapies. -
EGFR Inhibitor
Emupertinib is a highly potent inhibitor of the epidermal growth factor receptor (EGFR), demonstrating IC50 values of less than 0.3 nM for the EGFR d746-750/T790M/C779S mutant and up to 0.92 nM for wild-type EGFR. This compound effectively inhibits various EGFR mutations, including L858R/T790M/C797S and d746-750/C797S, making it a valuable tool for research on targeted therapies in cancer treatment. Its high specificity and efficacy position Emupertinib as a significant candidate for studying EGFR-related signaling pathways and developing novel anticancer agents. -
EGFR Inhibitor
EGFR-IN-22 is a selective inhibitor of the epidermal growth factor receptor (EGFR), demonstrating potent activity with IC50 values of 4.91 nM for wild type EGFR and 0.54 nM for the mutant variants EGFR L858R/T790M/C797S. This compound is valuable for preclinical research aimed at understanding the role of EGFR signaling in various cancers, particularly those harboring specific mutations associated with resistance to standard therapies. -
EGFR Inhibitor
EGFR-IN-38 is a selective inhibitor of the epidermal growth factor receptor (EGFR), which plays a critical role in cancer cell proliferation. This compound exhibits significant anti-tumor activity while maintaining low toxicity, making it a valuable tool in cancer research. Its mechanism of action addresses the overexpression and mutations of EGFR, commonly implicated in the development and progression of various malignancies, particularly non-small cell lung cancer (NSCLC). EGFR-IN-38 serves as a promising candidate for investigating EGFR-related pathologies and therapeutic strategies. -
EGFR/HER2 Inhibitor
EGFR/HER2-IN-7 is a selective inhibitor targeting the EGFR and HER2 kinases, demonstrating potent antitumor activity in MCF-7 breast cancer cells. With IC50 values of 0.18 μM for EGFR and 0.146 μM for HER2, it effectively impedes signaling pathways involved in cancer progression. Additionally, EGFR/HER2-IN-7 exhibits moderate inhibition of dihydrofolate reductase (DHFR) with an IC50 of 0.907 μM. This compound is relevant for research focused on therapeutic strategies for breast cancer and the modulation of related signaling pathways. -
EGFR Inhibitor
EGFR-IN-81 is a potent inhibitor of the epidermal growth factor receptor (EGFR), specifically targeting both wild-type and mutant forms (L858R/T790M) with IC50 values of 4.38 nM and 5.69 nM, respectively. This compound exhibits significant cytotoxic effects on cancer cell lines, demonstrating inhibitory concentrations of 2.07 μM against MCF-7 cells and 6.72 μM against HCT116 cells. EGFR-IN-81 is useful for research applications focused on cancer biology and therapeutic development targeting EGFR-driven malignancies. -
EGFR Inhibitor
VEGFR-IN-4 is a potent epidermal growth factor receptor (EGFR) inhibitor. It demonstrates significant antiproliferative activity, exhibiting an IC50 value of 24.6 nM against HCC827 cells. This compound is primarily utilized in research focused on cancer therapeutics, particularly in studies exploring EGFR-mediated signaling pathways and tumor growth inhibition. -
EGFR Inhibitor
EGFR-IN-50 is a potent inhibitor of the epidermal growth factor receptor (EGFR), specifically targeting the L858R resistance mutation. It exhibits strong anti-proliferative activity in cancer cells, with a GI50 of 8 nM against TEL-EGFR-L858R-BaF3 cells and 6.03 μM against TEL-EGFR-T790M-L858R-BaF3 cells. This compound is valuable for research applications focused on overcoming resistance in EGFR-driven cancers. -
EGFR Inhibitor
NSC381467 is a potent, orally active inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. This compound exhibits significant antiproliferative activity, making it a valuable tool in cancer research. NSC381467 is suitable for studies aimed at understanding EGFR-mediated signaling pathways and their implications in tumor biology. -
EGFR Inhibitor
EGFR-IN-179 is a selective inhibitor of the epidermal growth factor receptor (EGFR), demonstrating an IC50 of 0.068 μM for the EGFR L858R/T790M/C797S mutant and 2.56 μM for wild-type EGFR. This compound exhibits significant anticancer activity, particularly against non-small cell lung cancer, making it a valuable tool for research into targeted therapies and understanding resistance mechanisms in cancer treatment. -
EGFR Inhibitor
EGFR-IN-451 is a potent EGFR inhibitor, demonstrating an IC50 value of 0.02 nM. This compound effectively targets mutant variants of EGFR, including EGFRL858R, EGFRT790M, and EGFRL858R/T790M, with IC50 values ranging from 0.26 to 34 nM. EGFR-IN-451 significantly inhibits the activation of downstream signaling proteins AKT and ERK, leading to reduced proliferation in EGFR-mutant cancer cell lines. It is suitable for research focused on EGFR-driven malignancies. -
EGFR Inhibitor
Z118332870 is a potent inhibitor of the epidermal growth factor receptor (EGFR) and bromodomain-containing protein 4 (BRD4). This compound displays significant antitumor activity, making it a promising candidate for addressing resistance mechanisms in cancer therapy. Its dual targeting capability may enhance therapeutic efficacy in various cancer types. -
EGFR/HER2/CDK9/COX-2 Inhibitor
CDK9-IN-41 is a potent inhibitor of CDK9, EGFR, HER2, and COX-2, exhibiting IC50 values of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM respectively. This compound demonstrates significant antitumor activity across various cancer cell lines, including leukemia, colon, melanoma, ovarian, and breast cancer. It serves as a valuable tool for exploring the role of these kinases in cancer biology and therapeutic applications. -
EGFR/HER2/DHFR Inhibitor
EGFR/HER2/DHFR-IN-1 is a selective inhibitor targeting the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and dihydrofolate reductase (DHFR). This compound demonstrates potent antitumor efficacy, with IC50 values of 0.153 μM for EGFR, 0.108 μM for HER2, and 0.291 μM for DHFR. EGFR/HER2/DHFR-IN-1 effectively arrests the cell cycle at the G1/S phase and promotes apoptosis in MCF-7 breast cancer cells, making it a valuable reagent for cancer research and therapeutic development. -
EGFR Inhibitor
SIQ17 is a potent inhibitor of the epidermal growth factor receptor (EGFR) that acts by binding to the ATP-binding site, exhibiting an IC50 of 0.62 nM. This compound demonstrates superior inhibitory activity against EGFR tyrosine kinase compared to Erlotinib, which has an IC50 of approximately 20 nM. SIQ17 is applicable in cancer research, particularly in studies focusing on EGFR-mediated signaling pathways and therapeutic resistance.
